Article
Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.
Cancer research - 1 Oct 2009
Konstantinidou Georgia, Bey Erik A, Rabellino Andrea, Schuster Katja, Maira Michael S, Gazdar Adi F, Amici Augusto, Boothman David A, Scaglioni Pier Paolo
Abstract excerpt
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death worldwide. NSCLC often harbors oncogenic K-RAS mutations that lead to the aberrant activation of several intracellular networks including the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway. Oncogenic K-RAS predicts poor prognosis and resistance to treatment with ionizing radiation (IR)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.